65,437 trials
HIV Infections
Primary: Proportion of Participants With New Grade 3 or Greater Adverse Events — 0; 0 proportion of participants
Acne
Primary: Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12 — -21.9; -13.9 lesion count — p=<0.001
Prostate Cancer
Primary: Percent Change Assessed by FACBC PET Scan — 3.2; 23.5 percent change of SUVmax
Generalized Anxiety Disorder
Primary: Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score — 13.1; 12.0; 11.2 Score on scale — p=0.0830
Type II Diabetes Mellitus
Primary: Change in Plasma Glucose Concentration — -29.7; -17.2; 3.1; 0.9 mg/dl
Burns
Primary: Change in Wound Appearance From Initial Injury Until Wound Healed — 43; 51 Burns
Gastrointestinal Problems · Autism Spectrum Disorders
Primary: Gastrointestinal Symptom Responsiveness Scale (GSRS) — 2.74; 1.31 units on a scale — p=<0.001
Helminthic Infection
Primary: Number of Subjects Reporting Adverse Events (AEs) Related to Oxfendazole for Arms 1, 2, and 3 — 3; 3; 1 Participants
Metastatic Prostate Cancer
Primary: Evidence of Metastatic Prostate Cancer — 0; 36; 0; 10 Participants
Healthy Volunteer
Primary: Metabolic Profile: Percentage of Free Thiophenol M1 in the Blood Plasma — 37.5 Percentage of Free Thiophenol M1
Colorectal Carcinoma
Primary: Pharmacological Effect on Cyclic Guanosine Monophosphate (cGMP) Levels for Dolcanatide Arm Versus (vs.) Placebo, as Measured by the Differences in Mean cGMP Levels After…
Severe Hemophilia A
Primary: Immunogenicity of Human-cl rhFVIII: Incidence of Inhibitors — 0 participants
Head and Neck Cancer
Primary: Overall Response Rate (ORR) — 1; 14; 15; 5 participants
Airway Morbidity
Primary: Number of Subjects Who Present With Postoperative Sore Throat — 71; 71; 67 Participants
Type 1 Diabetes
Primary: HbA1c — 7.77; 7.94; 7.64; 7.60 percent